Clinical Trial

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Study acronym: DeLLphi-311
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-06-17; most recent amendment 2026-05-27.
Status change: Not Yet Recruiting → Recruiting 2025-10-02
Trial Details
NCT Number NCT07037758
Lead Sponsor Amgen
Collaborators: Asher Biotherapeutics, Inc.
Conditions Extensive Stage Small Cell Lung Cancer
Enrollment 380 participants
Start Date 2025-09-16
Primary Completion 2028-03-18 (estimated)
Study Completion 2031-01-18 (estimated)
Updated on ClinicalTrials.gov 2026-05-29